IDO-derived peptide vaccine/PD-L1-derived peptide vaccine (IO Biotech)

Pipeline Progress: Over 25 New Therapies in Development for Metastatic Liver Cancer

2 months ago

• DelveInsight's latest report reveals a robust pipeline with over 20 companies developing 25+ therapies for metastatic liver cancer, offering new hope for patients with limited treatment options. • Several promising clinical trials are underway in 2025, including studies evaluating novel combinations such as AK104 plus lenvatinib, tislelizumab with lenvatinib, and triplet therapy of nivolumab, relatlimab and bevacizumab. • Key emerging therapies include exoASO-STAT6 targeting tumor-associated macrophages, STP705 dual TGF-ß1/COX-2 inhibitor, and ONCR-177, an oncolytic viral immunotherapy expressing five transgenes to fight tumors through multiple mechanisms.

IO Biotech Completes Enrollment in Phase 2 Trial of IO102-IO103 Cancer Vaccine

4 months ago

• IO Biotech has completed enrollment in its Phase 2 basket trial (IOB-032/PN-E40) evaluating IO102-IO103 in combination with pembrolizumab. • The trial includes patients with resectable melanoma or squamous cell carcinoma of the head and neck (SCCHN) receiving neoadjuvant/adjuvant treatment. • Initial data from the Phase 2 trial, which enrolled 93 patients across multiple sites, is expected in 2025. • The primary endpoint is major pathological response (MPR), with secondary endpoints including pCR, ORR, DFS, EFS, and safety.

IO Biotech Faces Nasdaq Delisting Risk Despite Promising Cancer Vaccine Advances

5 months ago

• IO Biotech received a Nasdaq warning for its stock price falling below $1.00 for 30 consecutive days, risking delisting. • The company has until June 2025 to regain compliance by maintaining a stock price above $1.00 for at least 10 days. • Recent data from a Phase 2 trial of IO102-IO103 showed potential in treating metastatic non-small cell lung cancer. • A €57.5 million loan from the EIB aims to advance IO Biotech's cancer vaccine development, extending financial runway into Q2 2026.

IO Biotech's IO102-IO103 Plus Pembrolizumab Shows Promise in Head and Neck Cancer

8 months ago

• IO Biotech's Phase 2 trial of IO102-IO103 with pembrolizumab demonstrates a 44.4% overall response rate in PD-L1 high recurrent or metastatic SCCHN patients. • The combination therapy shows an encouraging median progression-free survival of 6.6 months and a disease control rate of 66.7% in SCCHN. • The safety profile of IO102-IO103 with pembrolizumab is consistent with previous studies, showing no new systemic toxicity concerns. • These results support further investigation of IO102-IO103 plus pembrolizumab as a first-line treatment for advanced head and neck cancer.

IO Biotech's Melanoma Trial of IO102-IO103 Combination Therapy to Continue

9 months ago

• IO Biotech's Phase III trial of IO102-IO103 with pembrolizumab for advanced melanoma will continue following IDMC review. • The IDMC found no new safety signals, supporting the ongoing evaluation of the therapeutic vaccine combination. • The primary endpoint, progression-free survival, is projected to be reached in the first half of 2025. • The trial compares IO102-IO103 plus pembrolizumab to pembrolizumab alone in previously untreated patients.